Barclays raised the firm’s price target on Syneos Health to $45 from $30 and keeps an Underweight rating on the shares after Reuters reported that the company is putting itself up for sale. The analyst’s sum-of-the-parts analysis shows "significant potential upside" to current shares from the business breaking up. However, the firm has limited confidence in Syneos Health’s fundamentals in 2023 and 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SYNH:
- Syneos Health launches Decentralized Clinical Trial Site Network
- Syneos Health Unveils New Decentralized Clinical Trial Site Network to Drive DCT Adoption
- Baird sees more value in Syneos than market, but says buyer would ‘need resolve’
- Syneos Health jumps following report on new effort to sell itself
- Syneos Health hires Bank of America to help seek buyer, Reuters says